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Abstract Testosterone deﬁciency is commonly associated
with obesity, metabolic syndrome, type 2 diabetes and their
clinical consequences—hepatic steatosis and athero-
sclerosis. The testicular feminised mouse (non-functional
androgen receptor and low testosterone) develops fatty liver
and aortic lipid streaks on a high-fat diet, whereas
androgen-replete XY littermate controls do not. Testoster-
one treatment ameliorates these effects, although the
underlying mechanisms remain unknown. We compared the
inﬂuence of testosterone on the expression of regulatory
targets of glucose, cholesterol and lipid metabolism in
muscle, liver, abdominal subcutaneous and visceral adipose
tissue. Testicular feminised mice displayed signiﬁcantly
reduced GLUT4 in muscle and glycolytic enzymes in muscle,
liver and abdominal subcutaneous but not visceral adipose
tissue. Lipoprotein lipase required for fatty acid uptake was
only reduced in subcutaneous adipose tissue; enzymes of fatty
acid synthesis were increased in liver and subcutaneous tissue.
Stearoyl-CoA desaturase-1 that catalyses oleic acid synthesis
and is associated with insulin resistance was increased in
visceral adipose tissue and cholesterol efﬂux components
(ABCA1, apoE) were decreased in subcutaneous and liver
tissue. Master regulator nuclear receptors involved in meta-
bolism—Liver X receptor expression was suppressed in all
tissues except visceral adipose tissue, whereas PPARγ was
lower in abdominal subcutaneous and visceral adipose tissue
and PPARα only in abdominal subcutaneous. Testosterone
treatment improved the expression (androgen receptor inde-
pendent) of some targets but not all. These exploratory data
suggest that androgen deﬁciency may reduce the buffering
capability for glucose uptake and utilisation in abdominal
subcutaneous and muscle and fatty acids in abdominal sub-
cutaneous. This would lead to an overspill and uptake of
excess glucose and triglycerides into visceral adipose tissue,
liver and arterial walls.
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Introduction
Evidence suggests that testosterone deﬁciency in men is an
independent cardiovascular risk factor which is associated with
obesity, metabolic syndrome (MetS) and type-2 diabetes
(T2D) [1, 2]. Insulin resistance, which is common to all of
these conditions, results in diminished glucose utilisation and
conversion of the excess glucose into fat. Higher circulating
triglycerides then lead to an overspill of fat into ectopic storage
in liver and arteries as well as increasing the accumulation of
visceral fat. The degree of insulin resistance correlates nega-
tively with serum testosterone [3, 4]. Although the causality of
this relationship is often debated, growing evidence indicates
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testosterone is a metabolic multi-system player [5]. Epide-
miological studies support a bidirectional relationship between
serum testosterone and obesity which may be explained
by the hypogonadal–obesity–adipocytokine hypothesis [6, 7].
Androgen deprivation therapy for the treatment of prostate
cancer in men, whilst reducing tumour growth, also increases
the risk of coronary heart disease, diabetes and cardiovascular
death, indicating that testosterone deﬁciency may promote
atherosclerosis [8, 9]. Some trials have reported that achieving
a normal physiological testosterone concentration through the
administration of testosterone replacement therapy (TRT)
improves vascular function and risk factors for atherosclerosis,
including reducing central adiposity, percentage body fat, fatty
liver and insulin resistance, and improving lipid proﬁles
insulin sensitivity and inﬂammatory proﬁles [2, 10–15].
A limited number of in vivo and in vitro investigations have
highlighted potential molecular targets of testosterone action in
metabolic regulation, although a detailed analysis of tissue-
speciﬁc actions remains absent from the literature [2]. We have
previously reported that low testosterone in the testicular
feminised (Tfm) mouse (which displays very low testosterone
levels and non-functional androgen receptors) is associated
with increased lipid deposition in the aortic root and liver
when mice are fed a high-cholesterol diet [16–18]. Testoster-
one treatment to return levels to those seen in wild-type
counterparts signiﬁcantly reduced aortic fatty steaks and
hepatic lipid accumulation with an associated reduction in de
novo lipogenesis in the liver in Tfm mice [17].
While a growing body of evidence points towards the
presence of heterogeneity regarding insulin responsiveness and
lipid homeostasis among different tissues [19], the mechan-
isms by which testosterone may impart beneﬁcial actions on
insulin sensitivity and hence the development of MetS, T2D
and cardiovascular risk remain unknown but are likely to be
tissue dependent and involve multiple targets of lipid and
carbohydrate metabolism. In the present exploratory study, we
aim to investigate whether the metabolic protective effects of
testosterone act via modulation of the expression of key targets
involved in lipid and glucose metabolism in muscle, liver and
adipose tissue of cholesterol-fed Tfm mice. Speciﬁcally, we
investigate key regulatory enzymes of glycolysis, glycogen
synthesis, pentose phosphate pathway, glucose transporters,
fatty acid synthesis, fatty acid uptake, cholesterol synthesis and
efﬂux, and master regulators of metabolism (see Table 1).
Materials and methods
Animals
The Tfm mouse was used as a model of testosterone deﬁ-
ciency and androgen receptor (AR) dysfunction as pre-
viously described [16–18]. The loss of 17α-hydroxylase, a
key enzyme necessary for testosterone synthesis, leads to
serum levels of testosterone in the Tfm mouse that are
severely (approximately 10-fold) reduced compared to
normal XY littermate controls [20, 21]. In addition, a nat-
ural mutation in the gene encoding the AR leads to the
formation of a truncated receptor protein which lacks both
DNA-binding and steroid-binding domains, rendering it
non-functional [22, 23]. This model therefore allows
potential AR-dependent and independent effects to be
investigated. All procedures were carried out under the
jurisdiction of a UK Home Ofﬁce project licence, governed
by the UK Animals Scientiﬁc Procedures Act 1986. Mice
were bred as previously described [20]. Animal numbers
were calculated based on our previous investigation [16] for
a signiﬁcance level of 5 %, and a power of 90 % for the
primary outcome measure of lipid deposition in the aortic
root (see [18]). Where available, preliminary data was used
for calculation of sample numbers of individual variables.
Experimental design and tissue collection
Eight-week-old Tfm and XY littermate mice were fed a high-
fat, high-cholesterol diet, containing 42% butterfat, 1.25%
cholesterol and 0.5% cholate (Special Diet Services, Essex,
UK) ad libitum for a period of 28 weeks. Separate 7-week-old
Tfm mice were ﬁrst randomly assigned to one of two groups: a
placebo group receiving a once-fortnightly intramuscular
injection of 10 μL of saline (n= 14), or testosterone group
(n= 14) receiving a once-fortnightly intramuscular injection of
10 μL of 100mg/mL testosterone esters (Sustanon100; tes-
tosterone propionate 20mg/mL, testosterone phenylpropionate
40mg/mL and testosterone isocaproate 40mg/mL, Organon
Laboratories Ltd, Cambridge, UK), providing a dose of
50mg/kg, previously shown to replace circulating levels to
those of wild-type littermate mice [16]. XY littermate mice
(n= 14) received placebo injections (10 μL saline). Animals
were caged under standard conditions in a temperature and
humidity-controlled room on a 12-h light:12-h darkness cycle.
Water and food were unrestricted throughout the study.
At the end of the experimental period, which corre-
sponded with the midway point of the fortnightly injec-
tion cycle, whole blood was collected from the thoracic
cavity following mid-line sternotomy and severance of
the thoracic aorta. Following centrifugation, serum sam-
ples were frozen at −80 °C. The liver was removed from
the abdomen, skeletal muscle dissected from the quad-
riceps of the hind legs and fat tissue collected from
subcutaneous and visceral abdominal regions. The heart
with thoracic aorta attached was carefully dissected free
from the adventitia and perfused. Tissues were processed
for both histological and gene and protein expression
analysis and were archived for future analysis. Analyses
were made on individual samples.
Endocrine
Measurement of total testosterone and 17β-estradiol
Serum quantiﬁcation of total testosterone (DRG Instruments
GmBH, Marburg, Germany) and 17β-estradiol (Demeditec
Diagnostics, Kiel, Germany) was measured in duplicate via
ELISA (measurement range 0.2–16 ng/mL and 3–200 pg/mL,
respectively).
Quantitative analysis of mRNA
Total RNA was extracted from approximately 100 mg of
snap-frozen tissue, reverse transcribed and cDNA (2 μL)
used for qPCR, using commercial SYBR green reagents
(Qiagen) as described previously [17]. Primers were pur-
chased pre-validated (QuantiTech primer assays; Qiagen),
with speciﬁed ampliﬁcation efﬁciencies of 100% (±10 %)
(see Table 1). Primers for Β-2 microglobulin (B2m) were
also included and served as an internal reference control,
selected as the most stable gene from a panel of commonly
used reference genes (Gapdh, beta-actin, ribosomal protein
13A). Each reaction was carried out in triplicate with
cycling and detection of ﬂuorescent signal carried out using
an Agilent Mx3000P QPCR System. Results were corrected
for the expression of the house-keeping gene and normal-
ised to the XY littermates as a control. Relative copy
number was expressed as fold change 2-(ddCT).
Table 1 Qiagen qPCR primers
Target Gene Function Product ref.
Fatty acid synthase Fasn Catalyses the formation of long-chain fatty acids in fatty acid synthesis QT00149240
Acetyl coA carboxylase Acaca Essential role in regulating fatty acid synthesis QT01554441
Stearoyl-CoA desaturase 1 Scd1 Catalyses a rate-limiting step in the synthesis of unsaturated fatty acids. Key
enzyme in fatty acid metabolism.
QT00291151
Lipoprotein lipase Lpl Hydrolysis of triglycerides into free fatty acids QT01750469
Hormone sensitive lipase Lipe Hydrolyses stored triglycerides to free fatty acids QT00169057
3-hydroxy-3-methylglutaryl-CoA
reductase
Hmgcr Rate-controlling enzyme of the mevalonate pathway that produces
cholesterol
QT01037848
Sterol regulatory element-binding protein
1
Srebf1 Cholesterol biosynthesis and uptake, and fatty acid biosynthesis QT00167055
Sterol regulatory element-binding protein
2
Srebf2 Cholesterol biosynthesis and uptake, and fatty acid biosynthesis QT01045870
Apolipoprotein E Apoe Lipoprotein metabolism and transport. QT01043889
ATP-binding cassette transporter A1 Abca1 Major regulator of cellular cholesterol efﬂux and phospholipid homoeostasis QT00165690
ATP-binding cassette transporter G5 Abcg5 Cellular cholesterol efﬂux, promote biliary excretion of sterols. QT00157752
Insulin receptor substrate 1 Irs1 Transmitting signals from the insulin and insulin-like growth factor-1
(IGF-1) receptors to intracellular pathways in insulin signalling
QT00251657
Hexokinase 2 Hk2 Phosphorylates glucose to glucose 6-phosphate in the glycolytic pathway QT00155582
Hexokinase 4 (Glucokinase) Gck Phosphorylates glucose to glucose 6-phosphate in the glycolytic pathway QT00140007
Phosphofructokinase Pfk Converts fructose-6-phosphate to fructose-1,6-bisphosphate, one of the most
important regulatory enzymes of glycolysis
QT00159754
Carbohydrate-responsive element-
binding protein
Chrebp Activates of several regulatory enzymes of glycolysis and lipogenesis QT00125335
Glucose transporter 4 Glut4 Cellular glucose transport QT01044946
Glucose-6-phosphate dehydrogenase G6pdx Enzyme in the pentose phosphate pathway, often for tissues actively
engaged in biosynthesis of fatty acids
QT01748957
Glycogen synthase Gys Converts glucose to glycogen for storage, regulating glycogen/glucose levels QT00162099
Liver X receptor alpha Nr1h3 Nuclear receptor transcription factor regulating cholesterol, fatty acid, and
glucose homoeostasis
QT00113729
Peroxisome proliferator-activated
receptor alpha
Ppara Transcription factor and major regulator of lipid metabolism QT00137984
Peroxisome proliferator-activated
receptor gamma
Pparg Regulates fatty acid storage and glucose metabolism QT00100296
Beta 2 microglobulin B2m Reference gene QT01149547
Glyceraldehyde 3-phosphate
dehydrogenase
Gapdh Reference gene QT01658692
Endocrine
Western immunoblotting
In this exploratory study we selected targets that were sig-
niﬁcantly altered at the gene expression level for analysis by
western blotting. Due to low concentrations of protein
ascertainable from limited availability of adipose tissue,
western blotting was unable to be carried out on sub-
cutaneous and visceral samples. Protein was extracted from
200 mg of mouse liver or muscle tissue as previously
described [17]. In brief, 50 µg of total isolated protein was
separated by electrophoresis and transferred to nitrocellu-
lose membranes (BioRad, Hertfordshire, UK). Membranes
were blocked for 1 h in 5 % dried semi-skimmed milk
diluted in tris/glycine (TG) buffer containing 0.05 % Tween
20 (TGT; BioRad, UK). Primary antibodies were incubated
overnight at 4 °C diluted in either 5% bovine serum albu-
min/TGT, 5 % milk/TGT or 2.5 % milk/BSA (see Table 2).
Immunoreactive proteins were detected using anti-rabbit
IgG HRP-linked secondary antibody (1:500, Cell Signal-
ling) for polyclonal antibody detection or anti-mouse IgG
HRP-linked secondary antibody (1:500, Cell Signalling)
followed by a chemiluminescence peroxidase substrate kit
(Roche, Sussex, UK). Band intensities were quantiﬁed
using Genetools software (Syngene, Cambridge, UK) rela-
tive to the house-keeping protein GAPDH or Calnexin.
Statistical analysis
Results are presented as mean± SEM. Differences between
groups with normally distributed data were compared using
unpaired t tests without assuming consistent standard
deviations of groups. Mann–Whitney U tests were used
where data did not follow a normal distribution. Correc-
tions for multiple comparisons were made using the
Sidak-Bonferroni post hoc test. Signiﬁcance was accepted
at p≤ 0.05.
Results
Serum testosterone levels were greatly reduced in Tfm mice
(2.2 ± 1.2 nM, p= 0.03) compared to wild-type equivalents
(16.5 ± 4.3 nM).1 Testosterone treatment of Tfm mice
increased serum levels of testosterone comparable to wild-
type levels (14.7 ± 5.2 nM, p= 0.98). 17-β estradiol levels
were similar between all groups, Tfm mice (94.2±15.5
pmol) compared to wild-type (106.0 ± 33.9 pmol, p= 0.17)
and testosterone-treated Tfm mice (135.2 ± 28.7 pmol, p=
0.99). Animal weights and weight gain did not signiﬁcantly
differ between groups over the duration of the 28 week
feeding period but there was a trend towards Tfm mice
gaining more weight compared to littermates by the end of
the study period (p= 0.066, n= 14; Fig. 1).
Carbohydrate metabolism
Gene expression of the glycolytic regulatory gateway
enzymes hexokinase (Hk2, Gck) and Pfk was signiﬁcantly
lower in muscle (p= 0.012, p= 0.032), liver (p= 0.002,
p= 0.04) and SAT (p= 0.009, p= 0.03) but not in VAT of
Tfm-placebo mice compared to XY littermates (Table 3).
Testosterone administration increased Gck expression
(p= 0.015) in the liver of Tfm mice but these enzymes were
not signiﬁcantly altered in other tissues by treatment. Glut4
was similarly decreased in muscle (p= 0.015) and SAT
(p= 0.014) of Tfm mice versus wild-type mice, with no effect
of testosterone treatment. Hepatic G6pdx was elevated in Tfm
mice compared to XY mice (p< 0.001) and testosterone
treatment showed a trend to reducing this expression in Tfm
mice (p= 0.056). All other gene targets were not altered
between experimental groups in the tissues investigated.
Protein expression of PFK in the liver of experimental
animals matched gene expression data with reduced levels
in Tfm placebo mice compared to wild-type (p= 0.005) and
no effect of treatment with testosterone (Fig. 2). Muscle
protein expression of PFK was reduced in Tfm mice
(p= 0.018) with a signiﬁcant increase in expression fol-
lowing treatment (p= 0.01). Hepatic GCK protein was also
reduced in Tfm mice receiving placebo (p= 0.001) as
demonstrated at the gene level; however, testosterone
administration had no effect showing discrepancy between
gene and protein expression. HK2 in muscle was also
reduced at the protein level in Tfm mice (p= 0.024), but
there was no effect due to treatment. Muscle GLUT4 was
decreased in Tfm mice compared to wildtype (p= 0.037)
Table 2 Antibody parameters
Antibody Concentration Diluent Supplier
FASN 1:500 2.5 % milk bsa in tbs CST
ACACA 1:500 2.5 % milk bsa in tbs CST
ABCA1 1:250 2.5 % milk bsa in tbs abcam
APOE 1:250 5 % milk in tbs abcam
GCK 1:500 5 % milk in tbs abcam
PFK 1:250 0.01 % milk bsa in tbs Proteintech
GLUT4 1:500 2.5 % milk bsa in tbs CST
HK2 1:500 2.5 % milk bsa in tbs CST
LXR 1:500 1 % milk bsa in tbs abcam
G6PD 1:500 0.01 % milk bsa in tbs Sigma
GAPDH 1:5000 2.5 % milk bsa in tbs abcam
Calnexin 1:1000 5 % milk in tbs CST
bsa bovine serum albumin, tbs tris-buffered saline, CST cell signalling
technologies
1As previously published [16, 18, 20].
Endocrine
and testosterone administration demonstrated a trend
towards increasing this expression (p= 0.053). We were
unable to detect G6PD protein expression in the liver of
experimental animals.
Lipid metabolism
Cholesterol metabolism
Expression of cholesterol transporters, Apoe and Abca1,
were reduced in the liver of Tfm mice compared to litter-
mates (p= 0.009, p= 0.002). Treatment with testosterone
signiﬁcantly increased this expression (p= 0.027, p= 0.02),
similar to wild-type levels (Table 3). Similarly, Apoe was
decreased in SAT of Tfm mice (p= 0.01), an effect that was
abolished by testosterone administration (p= 0.015 versus
Tfm P). Srebf1 and Srebf2 expression was signiﬁcantly
lower in the SAT of Tfm mice versus XY littermates (p=
0.002, p= 0.003). Treatment with testosterone elevated
these expression levels of Srebf1 (p= 0.015) similar to
those demonstrated in wild-type mice although not sig-
niﬁcantly so for Srebf2 with only a trend towards increased
expression observed (p= 0.053). In support of gene
expression data, ABCA1 protein was signiﬁcantly reduced
Fig. 1 Animal weights and
weight gain. Tfm mice receiving
either placebo (Tfm P) or
testosterone (Tfm T) and wild-
type XY littermates receiving
placebo (XY P) had total body
weight (a) measured at
weekly intervals from the
commencement of high-
cholesterol diet feeding at week
8 through to the end of the study
at week 36. Weight gain (b) was
calculated from starting weights
of individual animals. No
signiﬁcant differences were
noted between groups
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in livers of Tfm mice compared to littermates and testos-
terone treated Tfms (Fig. 2). Hepatic APOE protein
expression matched gene expression data with signiﬁcantly
lower levels in placebo-treated Tfm mice compared to XY
littermates and testosterone-treated Tfm mice (p= 0.011,
p= 0.007, respectively).
Fatty acid metabolism
Visceral adipose Scd1 expression was signiﬁcantly higher
in Tfm mice receiving placebo than in XY littermates also
receiving placebo injections (p = 0.034, Table 3). Testos-
terone treatment of Tfm mice returned expression levels to
those of XY mice with a signiﬁcant reduction compared to
placebo-treated Tfm mice (p = 0.027). t test analysis
similarly revealed an increase in hepatic Scd1 expression
in Tfm placebo mice although not statistically signiﬁcant
(p = 0.08). Decreased Lpl expression was observed in SAT
from Tfm mice compared to wildtype (p = 0.016) although
testosterone administration to Tfm animals had no effect
on this. Hepatic gene expression of Fasn and Acaca, the
key regulatory enzymes in de novo lipogenesis, were
signiﬁcantly increased in Tfm mice receiving placebo
injections compared to wild-type littermates (p = 0.049, p
= 0.042, respectively).2 Testosterone treatment decreased
this expression but not signiﬁcantly. Gene expression of
all other lipid metabolism targets in liver and adipose
tissue were not signiﬁcantly different between animal
groups. Western blotting showed hepatic protein expres-
sion of FASN and ACACA to be increased in Tfm mice
conﬁrming gene expression ﬁndings.2 Testosterone treat-
ment signiﬁcantly reduced the protein expression of these
enzymes versus placebo treated Tfm mice to similar levels
as XY littermates.
No targets of fat metabolism and cholesterol homeostasis
displayed altered gene expression in muscle tissue from the
different experimental groups.
Master regulators
Gene expression of Lxr was signiﬁcantly reduced in Tfm
placebo mice in all tissues other than visceral adipose
(muscle p= 0.032, liver p< 0.001, SAT p= 0.003), and
testosterone administration increased expression signiﬁcantly
and back to wild-type levels in these tissues (muscle p=
0.008, liver p= 0.024, SAT p= 0.03). Ppara and Pparg
were signiﬁcantly reduced in SAT of Tfm mice receiving
placebo versus XY littermate controls (p= 0.01, p= 0.02,
respectively). Pparg was also reduced in visceral adipose
tissue of Tfm mice (p= 0.001). Testosterone treatment had
T
ab
le
3
(c
on
tin
ue
d)
M
as
te
r
R
eg
ul
at
or
s
M
us
cl
e
L
iv
er
S
ub
cu
ta
ne
ou
s
F
at
V
is
ce
ra
l
F
at
G
en
e
S
ym
bo
l
X
Y
-P
T
fm
-P
T
fm
-S
10
0
X
Y
-P
T
fm
-P
T
fm
-S
10
0
X
Y
-P
T
fm
-P
T
fm
-S
10
0
X
Y
-P
T
fm
-P
T
fm
-S
10
0
L
iv
er
X
re
ce
pt
or
L
X
R
1.
35
±
0.
29
0.
62
±
0.
12
*
1.
50
±
0.
27
†
†
1.
05
±
0.
09
0.
66
±
0.
08
**
1.
28
±
0.
24
†
1.
07
±
0.
14
0.
42
±
0.
13
**
1.
15
±
0.
28
†
1.
27
±
0.
35
1.
00
±
0.
30
1.
44
±
0.
48
P
er
ox
is
om
e
pr
ol
if
er
at
or
-a
ct
iv
at
ed
re
ce
pt
or
al
ph
a
P
P
A
R
a
1.
16
±
0.
20
1.
65
±
0.
78
0.
94
±
0.
21
1.
02
±
0.
07
1.
84
±
0.
55
0.
93
±
0.
14
1.
13
±
0.
23
0.
41
±
0.
11
0.
69
±
0.
22
1.
09
±
0.
20
0.
92
±
0.
32
0.
98
±
0.
22
P
er
ox
is
om
e
pr
ol
if
er
at
or
-a
ct
iv
at
ed
re
ce
pt
or
ga
m
m
a
P
P
A
R
g
1.
29
±
0.
31
1.
29
±
0.
62
0.
63
±
0.
17
1.
09
±
0.
14
0.
99
±
0.
19
1.
29
±
0.
23
1.
06
±
0.
14
0.
67
±
0.
06
0.
82
±
0.
12
1.
05
±
0.
11
0.
49
±
0.
08
**
*
0.
66
±
0.
10
R
el
at
iv
e
tis
su
e-
sp
ec
iﬁ
c
qP
C
R
en
d-
po
in
ta
na
ly
si
s
of
se
le
ct
ed
ge
ne
s
of
(a
)
fa
tm
et
ab
ol
is
m
,(
b)
ch
ol
es
te
ro
lh
om
eo
st
as
is
,(
c)
ca
rb
oh
yd
ra
te
m
et
ab
ol
is
m
an
d
(d
)
m
as
te
r
re
gu
la
to
rs
be
tw
ee
n
T
fm
pl
ac
eb
o-
tr
ea
te
d
ve
rs
us
X
Y
lit
te
rm
at
es
pl
ac
eb
o-
tr
ea
te
d,
an
d
T
fm
pl
ac
eb
o-
tr
ea
te
d
ve
rs
us
T
fm
te
st
os
te
ro
ne
-t
re
at
ed
.N
=
11
.*
p
<
0.
05
,*
*p
<
0.
01
,*
**
p
<
0.
00
1
ve
rs
us
X
Y
pl
ac
eb
o,
†
p
<
0.
05
,†
†
p
<
0.
01
ve
rs
us
T
fm
pl
ac
eb
o,
a p
=
0.
05
3,
b
p
=
0.
05
8,
c p
=
0.
05
6.
2As previously published [15].
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no effect on the altered expression of Ppars when compared
to placebo treated Tfm mice (see Table 3).
LXR protein expression in liver and muscle demon-
strated the same pattern indicated by gene expression ana-
lysis with a reduction in Tfm placebo mice compared to
wild-type littermates (p= 0.001, p= 0.01). Treatment with
testosterone elevated LXR levels signiﬁcantly in liver and
muscle (p= 0.024, p= 0.022), to similar levels seen in
placebo-treated Tfm mice (Fig. 2).
Discussion
Exploratory evidence from this study suggests that testos-
terone has tissue-speciﬁc metabolic effects in the regulation
of gene targets which control glucose utilisation in liver,
SAT and skeletal muscle, and lipid metabolism in liver and
SAT. Some of these effects are, at least in part, androgen
receptor-independent and may potentially explain some of
the observed clinical beneﬁt of testosterone in men with
T2D and MetS.
Testosterone effects on expression of targets of glucose
metabolism
GLUT4 expression is known to correlate positively with
insulin responsiveness and defects in expression of GLUT4
have been observed in patients with T2D [24]. We have
shown that there is decreased expression of GLUT4 in
muscle and SAT in the testosterone deﬁcient Tfm mouse.
Testosterone has previously been shown to increase the
expression of GLUT4 in cultured skeletal muscle cells,
hepatocytes and adipocytes [25–27] as well as augment-
ing membrane translocation and promoting glucose
uptake in adipose and skeletal muscle tissue [27]. Key
enzymes involved in glycolysis, PFK and HK, were sig-
niﬁcantly reduced in muscle, liver and SAT of Tfm mice.
This supports previous studies which have demonstrated
an increase in the activity of PFK and HK in cultured rat
skeletal muscle cells and increased hexokinase activity in
muscle tissue of castrated rats following testosterone
treatment thus diminishing the raised blood levels of
glucose seen in untreated control rats [27–29]. Improved
glucose utilisation in muscle, liver and SAT by testos-
terone may reduce the conversion of glucose to fat in
times of excess and improve insulin sensitivity thus
reducing lipid accumulation in these and other tissues.
This clinically would be very important in muscle as this
tissue accounts for approximately 75 % of whole-body
insulin-stimulated glucose uptake [30, 31].
We have also demonstrated in this study that the mRNA
expression of Glucose-6-phosphate dehydrogenase (G6pd),
the gateway enzyme in the pentose phosphate shunt path-
way, is elevated in the liver of Tfm mice suggesting that
glucose may also be utilised down this route during tes-
tosterone deﬁciency. NADPH is produced by G6PD in the
Fig. 2 Protein expression of selected targets of lipid and glucose
regulation in muscle and liver of Tfm mice. Semi quantitative western
blot analysis in (a) muscle and (b) liver of Tfm mice receiving either
placebo or testosterone and wild-type XY littermates receiving placebo
at the end of the study period. Data are presented as densitometry
arbitrary units and representative blot images. N= 6. *p< 0.05 versus
XY placebo, †p< 0.05 versus Tfm placebo
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pentose phosphate pathway supplying reducing power to
contribute to fatty acid synthesis [32]. An aberrant increase
of G6PD expression is present in obese and diabetic sub-
jects, and overexpression of G6PD alters lipid metabolism,
impairs insulin signalling and suppresses insulin-dependent
glucose uptake in mouse adipocytes [32]. However, the
exact role of hepatic G6PD in metabolic function is
unknown.
Testosterone effects on expression of targets of lipid
metabolism
In the present study we demonstrate that testosterone deﬁ-
ciency negatively alters the expression of targets of lipid
metabolism primarily in liver and SAT but had little effect
in VAT. Decreased Lpl in Tfm mice with low testosterone
may limit the hydrolysis of lipoproteins and the subsequent
uptake of FFA into SAT. A previous study, however, has
shown the expression of hormone sensitive lipase and LPL
to be elevated in SAT of male mice with a selective adi-
pocyte AR knockdown (fARKO) [33]. These mice were fed
a normal chow diet and therefore LPL increase in the
absence of testosterone activated AR signalling may reﬂect
elevated subcutaneous lipid storage and decreased trigly-
ceride usage as an energy source in other tissues in times of
low fat intake. Treatment of hypogonadal men with TRT for
9 months resulted in a marked decrease in both LPL activity
and triglyceride uptake in abdominal adipose tissue [34].
Following further investigation, although LPL expression or
activity was not reported, the inhibition of lipid uptake after
testosterone administration was apparent in visceral
(omental plus mesenteric) and retroperitoneal but increased
in abdominal SAT suggesting that inhibition of triglyceride
assimilation may direct lipid to subcutaneous fat in TRT-
treated men and may therefore involve altered lipase
activity or expression in speciﬁc tissues [35], as suggested
in the present study.
Human SCD1 is a critical control point of lipid parti-
tioning with high SCD activity favouring fat storage and
suppression of the enzyme activating metabolic pathways
that promote the burning of fat and decrease lipid synthesis
[36]. Mice with a targeted disruption of the Scd1 gene have
very low levels of VLDL and impaired triglyceride and
cholesterol ester biosynthesis, as well as markedly reduced
adiposity and decreased hepatic steatosis on both lean and
ob / ob background despite higher food intake [37, 38]. In
the present study we demonstrate signiﬁcantly increased
Scd1 expression in VAT of Tfm mice and a trend towards
increased expression in the liver. Beyond its role in fatty
acid biosynthesis, SCD1 is an important factor in the
pathogenesis of lipid-induced insulin resistance with SCD1
deﬁciency up-regulating insulin-signalling components and
glycogen metabolism in insulin-sensitive tissues [38]. This
suggests that testosterone has the potential to improve both
lipid and glucose metabolism via reducing Scd1 expression
in VAT and the liver of Tfm mice.
Lower subcutaneous Apoe expression in testosterone deﬁ-
cient Tfm mice may be indicative of decreased reverse cho-
lesterol transport delivery of lipoproteins and cholesterol from
SAT to the liver for clearance. This difference was not
apparent in VAT supporting an important depot-speciﬁc role
of APOE in adipose tissue substrate ﬂux and accumulation of
triglyceride in these depots [39]. Additionally, in the present
study we demonstrate that mRNA expression of Srebf1 and
Srebf2, key transcription factors and master regulators of
lipogenesis [40], were signiﬁcantly decreased in SAT of Tfm
mice compared to testosterone treated animals and wild-type
controls. Similarly, orchidectomy signiﬁcantly reduced hepatic
SREBP-1 expression in mice fed a high fat diet or normal
chow, an effect that was ameliorated by testosterone treatment
in high fat diet conditions [41]. As SREBPs are known to
directly induce transcription of many genes needed for uptake
and synthesis of cholesterol, fatty acids, triglycerides and
phospholipids [42]; taken together, these data lead us to
hypothesise that testosterone deﬁciency may diminish SAT
metabolic function and reduce lipid storage capacity.
Increased liver fat in Tfm mice from the present study is
considered partly due to increased de novo lipogenesis and
the expression of FASN and ACACA [17], which supported
earlier studies indicating that a lack of testosterone action
results in hepatic lipid accumulation [41–43]. The present
study additionally indicates that ABCA1 and APOE,
involved in cholesterol and lipoprotein efﬂux, are reduced
in the testosterone-deﬁcient state in the liver of Tfm mice.
The overexpression of hepatic Abca1 in transgenic mice
results in a marked increase in HDL release, decreased LDL
and signiﬁcantly reduced atherosclerosis when compared
with control mice [44]. Furthermore, increased hepatic
cholesterol content was reported in these mice as the level
of expression of the ABCA1 transporter decreased [45].
Indeed, Tfm mice from the present study have elevated total
cholesterol and LDL compared to wild-type mice [18].
Therefore, the increased hepatic lipid accumulation in our
Tfm mice may additionally result from absence of beneﬁcial
testosterone effects on lipid transport.
Testosterone effects on master regulators of lipid and
glucose metabolism
Testosterone altered the expression of master metabolic reg-
ulators as a potential signalling mode of action to inﬂuence
lipid and glucose regulation. Reduced expression of the
nuclear receptor, liver X receptor (LXR), in muscle, liver and
SAT of Tfm mice compared to testosterone-replete animals
whether with or without AR function leads to the hypothesis
that testosterone may increase LXR signalling to exert some of
Endocrine
its protective metabolic effects. LXRs are key transcriptional
regulators of lipid and carbohydrate metabolism known to
control molecular pathways including cholesterol efﬂux, glu-
cose regulation, fatty acid synthesis and inﬂammation [46]. In
parallel with testosterone-associated changes in LXR expres-
sion in the present study, we saw alterations in known LXR
target genes: Fasn, Apoe, Abca1, Lpl, Srebpf1. Rather than
inducing hepatic steatosis as with many LXR agonists, tes-
tosterone additionally protects against diet-induced hepatic
lipid accumulation in this model [17]. Tfm mice also had
reduced SAT and VAT expression of Pparg mRNA, indi-
cating a potential mechanism by which testosterone deﬁciency
may lead to metabolic dysregulation and adverse fat dis-
tribution. Additionally, Tfm mice displayed lower SAT Ppara
(a master regulator of fatty acid oxidation) expression, sug-
gesting that testosterone deﬁciency may further inhibit lipid
regulation.
The present study indicates that testosterone may sig-
nal, at least in part, beyond its classical nuclear AR to
modulate targets of lipid and glucose metabolism and that
these actions are further differentially dependent on the
target tissue. Whether the AR-independent effects in this
study are via conversion to estradiol and subsequent
activation of the oestrogen receptor (ER) was not
addressed. We have previously shown, however, that
testosterone has additional actions on hepatic and aortic
lipid accumulation in Tfm mice even with aromatase
inhibition and ER blockade [16, 17]. Further investigation
is required to elucidate the AR-independent signalling
mechanisms of testosterone action.
Limitations
The present exploratory study is limited to target expression
data, and while it indicates potential metabolic effects of tes-
tosterone it does not directly assess metabolic function. Lack
of tissue prevented protein analysis of SAT and VAT due to
the reduced amounts of protein recoverable from available
adipose tissue. In addition, the Tfm mouse is a model of global
AR dysfunction and severely reduced testosterone levels from
birth, therefore we cannot rule out any developmental effects
of these factors on tissues which may inﬂuence the patho-
genesis of metabolic disorders. Whilst the testosterone injec-
tions produce levels within the normal range, diurnal patterns
are absent and supraphysiological levels in the ﬁrst few days
are apparent with near-infraphysiologic levels towards the end
of the interval [16]. Such administration may explain the
inﬂuence of testosterone treatment on gene expression above
and beyond that observed in wild-type controls. An additional
orchidectomised XY littermate group receiving testosterone
treatment would also allow us to control for pharmacological
and dosing effects in animals with fully functional AR. These
issues should be addressed in future studies.
Conclusion
We present exploratory evidence that suggests testosterone
is a metabolic hormone that differentially regulates the
expression of key targets of lipid and glucose metabolism
in a tissue-speciﬁc manner to potentially reduce fat deposi-
tion in pathologically relevant locations such as liver and the
arterial tree. Indeed, as regional differences in the action of
testosterone on subcutaneous and visceral adipose function
are apparent, we hypothesise that low testosterone in the Tfm
mouse leads to decreased lipid uptake and glucose utilisation
in SAT resulting in its reduced capacity to act as a physio-
logical ‘buffer’ in times of positive energy balance. This
decreased ability to store excess lipid may then result in
spillover into other tissues. Tfm mice have increased lipid
accumulation in the aortic root and liver as early manifesta-
tions of atherosclerosis and hepatic steatosis. These effects
are signiﬁcantly reduced by testosterone replacement [17].
While this study adds support to the literature implicating
testosterone as a metabolic hormone, by combining expres-
sional data from multiple metabolic tissues with pathological
evidence that testosterone protects against the development
of hepatic steatosis and atherosclerosis, we now suggest a
system-wide androgenic action to offer new mechanistic
insight to the observed clinical beneﬁt of testosterone in men
with T2D and MetS.
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